Phase II Clinical Trial of Mifepristone an Eye Drop Treatment for Steroid Associated Elevated Intraocular Pressure第二期臨床試驗米非司酮1眼藥水治療類固醇相關的高眼壓
Wednesday, September 27th, 2006 週三, 2006年9月27日Global bio-nanotech company pSivida Limited (NASDAQ:PSDV) (ASX:PSD) (Xetra:PSI) today announced the initiation of a Phase II clinical trial of Mifepristone (otherwise known as RU486) as an eye drop treatment for steroid associated elevated intraocular pressure (IOP).全球生物納米技術公司psivida有限公司( NASDAQ : psdv ) (澳交所: PSD )的( xetra :防擴散安全倡議)今天宣布啟動一項二期臨床實驗中米非司酮(否則稱為米非司酮)作為一個眼藥水治療類固醇相關的高眼壓壓力(眼壓) 。
































